Evidence map›Paper›PMID 32477175›Full record

ArticleFrontiers in psychiatry2020

Feasibility of a Complex Setting for Assessing Sleep and Circadian Rhythmicity in a Fragile X Cohort.

Alexander Dueck, Olaf Reis, Manuela Bastian, Lucas van Treeck, Steffen Weirich, Frank Haessler, Andreas Fiedler, Michael Koelch, Christoph Berger

2 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06957054 completednot on this mapstarted 2024, after this paper: background citation

Assessment of Neural Biomarkers in Adult Subjects With Fragile X Syndrome and Typically Developing Subjects

TypeobservationalSponsorConnecta Therapeutics, S.L.Ran2024 to 2025Enrolled20ConditionsFragile X Syndrome (FXS), Neurotypical AdultsArmsAny
NCT07654114 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluation of the Safety, Tolerability, and Effectiveness of CTH120 in Adult Males With Fragile X Syndrome

TypeinterventionalSponsorConnecta Therapeutics, S.L.Ran2026 to 2027Enrolled30ConditionsFragile X Syndrome (FXS), Fragile X SyndromeArmsCTH120, CTH120 placebo hard capsules
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Alexander DueckDepartment for Psychiatry, Neurology, Psychosomatics and Psychotherapy in Childhood and Adolescence, Rostock University Medical Center, Rostock, Germany.
Olaf ReisDepartment for Psychiatry, Neurology, Psychosomatics and Psychotherapy in Childhood and Adolescence, Rostock University Medical Center, Rostock, Germany.
Manuela BastianInstitute for Clinical Chemistry and Laboratory Medicine, Rostock University Medical Center, Rostock, Germany.
Lucas van TreeckDepartment for Psychiatry, Neurology, Psychosomatics and Psychotherapy in Childhood and Adolescence, Rostock University Medical Center, Rostock, Germany.
Steffen WeirichDepartment for Psychiatry, Neurology, Psychosomatics and Psychotherapy in Childhood and Adolescence, Rostock University Medical Center, Rostock, Germany.
Frank HaesslerDepartment of Child and Adolescent Psychiatry, GGP Group, Rostock, Germany.
Andreas FiedlerDepartment for Pediatric and Adolescent Medicine, Klinikum St. Marien, Amberg, Germany.
Michael KoelchDepartment for Psychiatry, Neurology, Psychosomatics and Psychotherapy in Childhood and Adolescence, Rostock University Medical Center, Rostock, Germany.
Christoph BergerDepartment for Psychiatry, Neurology, Psychosomatics and Psychotherapy in Childhood and Adolescence, Rostock University Medical Center, Rostock, Germany.
University of Rostock · DEKlinikum St. Marien Amberg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSleep, circadian rhythms, (mental) health, and development are assumed to be intertwined. However, differentiated and reliable parameters of sleep and circadian rhythms are particularly difficult to assess for Fragile X (FXS) individuals. As those parameters need to be observed in complex settings, the feasibility of measurements for people with FXS was to be proven. Findings from this pilot study can inform further research and help to estimate sample sizes for future studies on FXS patients. METHODS AND SAMPLE: Nine individuals (male and female) with full mutation of the FMR1 gene were integrated in the study and underwent a complex measurement including actigraphy, sleep log, and 24-h saliva sampling in order to examine profiles of melatonin and cortisol, and a polysomnography.

resultsSeven actigraphy profiles, eight sleep logs, eight saliva profiles and seven polysomnographic data sets were collected. Complete data were analyzed for six individuals [mean age 14.87 years (SD 4.12), mean BMI 25.90 (SD 4.44)] were collected. No drop outs due to the constraints of the assessment were registered. DISCUSSION: All assessments and the setting in total were tolerated well by participants and caregivers. Procedures were adapted to individual needs of the participants.

conclusionAll its components and the setting in total are absolutely feasible in the specific population of FXS individuals. Losses during consenting and recruiting have to be planned as well as high amounts of interindividual variances have to be taken into account.

Indexed as

circadian rhythmFragile Xmelatoninpolysomnographysleep

Identifiers

PMID32477175
PMCPMC7240033
OpenAlexW3025593648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.